Investing.com - Autolus Therapeutics (NASDAQ: AUTL) reported first quarter EPS of $-0.240, $0.16 worse than the analyst estimate of $-0.080. Revenue for the quarter came in at $10.09M versus the consensus estimate of $33.4M.
Autolus Therapeutics's stock price closed at $4.07. It is up 0% in the last 3 months and up 48.000% in the last 12 months.
Autolus Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Autolus Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Autolus Therapeutics's Financial Health score is "weak performance".
Check out Autolus Therapeutics's recent earnings performance, and Autolus Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar